ライフサイエンスコーパス: p-

1 ows: aHR = 1.04 (95% CI 0.54-2.01), I2 = 0%, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and

2 and pre-treated eGFR (OR, 0.98 (0.95-1.00), p = 0.04).

3 U discharge (hazard ratio, 0.65 [0.42-1.00]; p = 0.01), longer delirium duration (incidence rate rati

4 nd disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

5 ation (risk ratio, 0.50 [95% CI, 0.25-1.01]; p = 0.05; low-quality evidence); no reduction in toleran

6 shock (relative risk = 1.007 [1.002-1.013]; p = 0.006), time-to-first antibiotic (relative risk = 1.

7 d controls (C/TTCTG: gamma(2) value = 0.014; p = 0.904).

8 tes (-0.09 SD/decade, 95% CI [-0.16, -0.02], p = 0.009).

9 disposition index (beta = 0.056, SE = 0.026; p = 0.035).

10 ceride GRS unit: 2.04; 95% CI: 1.03 to 4.03; p = 0.04).

11 = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603.

12 increased risk of death (hazard ratio: 2.05; p < 0.0001).

13 %, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603.

14 imit of reactivity, 1.04; 95% CI, 1.02-1.06; p < 0.001) and mortality (odds ratio, 1.06; 95% CI, 1.04

15 l shortening (z-score for difference = 1.07; p = 0.02) and HAART exposure duration (z-score differenc

16 tality (odds ratio, 1.06; 95% CI, 1.04-1.08; p < 0.001).

17 justed ICD HR: 0.921; 95% CI: 0.787 to 1.08; p = 0.31), whereas those with SPRM above the median deri

18 uation II (relative risk = 1.05 [1.02-1.09]; p = 0.003), Sequential Organ Failure Assessment (relativ

19 oma prevalence decreased from 20.0% to 7.1% (p = 0.003).

20 fraction (45.6 +/- 17.4% vs. 55.3 +/- 11.1%; p < 0.001).

21 per cm vessel (3.8 +/- 1.1 vs. 1.8 +/- 1.1; p = 0.010) and not associated with Intima Media thickeni

22 ire scores (56.2 +/- 26.8 vs. 31.7 +/- 22.1; p = 0.011) were observed.

23 action decreased (58 +/- 11% vs. 55 +/- 10%; p < 0.001; n = 259), and B-type natriuretic peptide incr

24 than 80% from baseline to day 4 (20% vs 10%; p = 0.001).

25 atus Scale (EDSS) assessments (beta = 1.105, p < 0.001) and presence of relapses (beta = 1.430, p < 0

26 vs usual care, 90/1,106 [8.1%]) (n = 2,112; p = 0.29; I, 25%; fixed effect model: odds ratio, 0.83;

27 OA patients (beta -0.41; 95% CI-0.69, -0.12; p < 0.005; adjusted for covariates) but not with radiogr

28 ans (-0.20 SD/decade, 95% CI [-0.28, -0.12], p < 0.001) than for whites (-0.09 SD/decade, 95% CI [-0.

29 hemorrhage (OR [95% CI] = 0.97 [0.84-1.12]; p = 0.71; 1,545 cases, 1,481 controls).

30 survivors 80 years old or older (30% vs 14%; p = 0.001).

31 p < 0.035), BDE-99 (p < 0.035), and BDE-153 (p < 0.039), from the adult's bedroom for BDE-99 (p < 0.0

32 uptake decreased (69 +/- 14% vs. 61 +/- 16%; p < 0.001; n = 95), ejection fraction decreased (58 +/-

33 hest tertile (OR = 0.92, 95% CI = 0.73-1.16, p = 0.49) when compared with the median tertile.

34 d (hazard ratio: 0.92; 95% CI: 0.73 to 1.16; p = 0.49).

35 intensities (OR [95% CI] = 1.10 [1.05-1.16]; p = 5.3 x 10(-5) ; N = 3,670), but not intracerebral hem

36 uration (z-score difference per year = 0.17; p = 0.003.

37 ascular risk factors (HR = 1.07 [0.98-1.17], p = 0.1374, and HR = 1.17 [0.96-1.42], p = 0.1206, respe

38 ssessment (relative risk = 1.09 [1.00-1.18]; p = 0.04), presence of shock (relative risk = 1.007 [1.0

39 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicating that normal CSF amyloid levels do n

40 s (r = 0.20, p = 0.050), and PCBs (r = 0.19, p = 0.022).

41 creased platelet count (hazards ratio, 1.19; p = 0.03) were associated with a reduced likelihood of c

42 ntia (HR per SD increase = 1.11 [1.03-1.19], p = 0.0044) and mixed or vascular dementia (HR = 1.21 [1

43 evalent among Hispanic women (1.6% vs. 0.2%; p < 0.001).

44 0.0001) and 65 Gy.cm(2) versus 59 Gy.cm(2) (p = 0.0001), respectively.

45 was observed between BMI 12 and 25 kg/m(2) (p = 0.007).

46 ted improvement in LF only (3 +/- 6 ml/m(2); p = 0.02).

47 als (r = 0.43, p = <0.001)), PAHs (r = 0.20, p = 0.050), and PCBs (r = 0.19, p = 0.022).

48 t-procedure bleeding favored LAAC (HR: 0.20; p = 0.0022; HR: 0.45; p = 0.03; HR: 0.59; p = 0.027; HR:

49 all rooms for BDE-99 (p < 0.020) and BB-209 (p < 0.048).

50 rvival (odds ratio, 1.15; 95% CI, 1.09-1.22; p < 0.001).

51 ogical brain tumor diagnosis (beta = -0.253, p < 0.001).

52 not related to a stented site (59% vs. 26%, p = 0.001).

53 at baseline and end of therapy, Z >/= -2.27, p </= .023.

54 d 3 hours (relative risk = 0.09 [0.03-0.27]; p < 0.0001).

55 pital mortality was similar (12.4% vs 10.3%; p = 0.635).

56 3, rho = 0.56, p < 0.05; n = 13, rho = 0.30, p = 0.317).

57 eath (hazard ratio, 1.07; 95% CI, 0.88-1.30; p = 0.52).

58 , was approximately 50% (p = 0.013) and 33% (p = 0.008) lower, respectively, than that of intact SLC4

59 ine difference 2231 pg/dl, 95% CI: 897-3566, p = 0.0013).

60 ntibiotic (relative risk = 1.22 [1.09-1.36]; p = 0.0006), antibiotic administration within 6 hours (r

61 A positive correlation (r = 0.37; p < 0.004) between academic performance and SRI was obse

62 , 4 hours (relative risk = 0.16 [0.06-0.39]; p = 0.0001), and 3 hours (relative risk = 0.09 [0.03-0.2

63 not beta oscillatory amplitudes (rho = 0.4, p = 0.009) and interhemispheric coherence (rho = 0.5, p

64 subset of river water samples (r(2) = 0.41; p < 0.0001; n = 75).

65 or vascular dementia (HR = 1.21 [1.04-1.41], p = 0.0163).

66 two groups (HR: 1.09; 95% CI: 0.84 to 1.42; p = 0.53).

67 .17], p = 0.1374, and HR = 1.17 [0.96-1.42], p = 0.1206, respectively).

68 feeds (risk ratio, 0.94 [95% CI, 0.62-1.42]; p = 0.77; low-quality evidence), and no change in the du

69 tal compounds (other heavy metals (r = 0.43, p = <0.001)), PAHs (r = 0.20, p = 0.050), and PCBs (r =

70 001) and presence of relapses (beta = 1.430, p < 0.001).

71 nd readmission 0.90, third readmission 0.44; p > 0.05).

72 ve specimens (0.10nmol/l, range = 0.00-0.45, p < 0.001).

73 avored LAAC (HR: 0.20; p = 0.0022; HR: 0.45; p = 0.03; HR: 0.59; p = 0.027; HR: 0.73; p = 0.035; HR:

74 F (hazard ratio: 1.27; 95% CI: 1.10 to 1.45; p = 0.001).

75 n 6 hours (relative risk = 0.20 [0.09-0.45]; p = 0.0001), 4 hours (relative risk = 0.16 [0.06-0.39];

76 t (29.6pg/ml, IQR = 20.9-41.8; beta = 1.461, p = 0.005 and beta = 1.902, p = 0.002, respectively).

77 st samples from the living rooms for BDE-47 (p < 0.035), BDE-99 (p < 0.035), and BDE-153 (p < 0.039),

78 the radial systolic peak strain (r = 0.478, p = 0.045).

79 summation operatorBDE-47, -99, -100 = 0.48, p = 0.09), but not dust PBDE.

80 9; p = 0.027; HR: 0.73; p = 0.035; HR: 0.48; p = 0.0003, respectively).

81 ion (incidence rate ratio, 2.47 [1.36-4.49]; p = 0.005), and increased risk for delirium the followin

82 seline septal T1 1277.4 ms, follow up 1271.5 p = 0.504).

83 reatment (odds ratio [OR], 3.97 (1.37-11.5), p = 0.01) and pre-treated eGFR (OR, 0.98 (0.95-1.00), p

84 ) and interhemispheric coherence (rho = 0.5, p = 0.002).

85 2.5 to 92.6) versus 82.4 (IQR: 67.6 to 93.5; p = 0.025) and were more likely to receive anticoagulati

86 nsfected COS-7 cells, was approximately 50% (p = 0.013) and 33% (p = 0.008) lower, respectively, than

87 s usual care, 204/1,300 [15.7%]) (n = 2,507; p = 0.08; I, 53%; random effect model: odds ratio, 0.63;

88 tphone data (surrogates: n = 13, rho = 0.56, p < 0.05; n = 13, rho = 0.30, p = 0.317).

89 cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01)

90 neutral genetic data (on average r = 0.574, p < 0.001).

91 tion between CSF NfL and sNfL (beta = 0.589, p < 0.001).

92 0; p = 0.0022; HR: 0.45; p = 0.03; HR: 0.59; p = 0.027; HR: 0.73; p = 0.035; HR: 0.48; p = 0.0003, re

93 th quintile) (OR = 3.23; 95% CI: 1.37, 7.59; p = 0.04 for BC-by-TL-interaction).

94 following day (odds ratio, 2.83 [1.27-6.59]; p = 0.02).

95 ansaction) in Berkeley stores declined 9.6% (p < 0.001) compared to estimates if the tax were not in

96 t differences in 5-year OS (36.7% vs. 44.6%, p = 0.4289) or 5-year LTP (73.3% vs. 67.9%, p = 0.8897)

97 o have commercial insurance (19.6% vs 10.6%; p < 0.001) than those who were seen initially at a local

98 in all 22 paced subjects (range, 9.9-48.6%; p < 0.001).

99 roups (36 of 126 [28.6%] vs. 6 of 79 [7.6%]; p < 0.001).

100 Evaluation III scores (49.2 vs 53.2 vs 68.6; p < 0.01).

101 of heparin strategies (hazards ratio, 1.62; p = 0.003).

102 (adjusted HR: 0.599; 95% CI: 0.530 to 0.677; p < 0.0001).

103 150 mL/min (hazards ratio, 1.00 [0.60-1.69]; p = 0.68).

104 nosed cases (48/77 (62.3%) vs 13/41 (31.7%), p < 0.001).

105 ol group it was found in 3 patients (0.7%), (p > 0.05).

106 hickening Area (26 +/- 5.4% vs. 28 +/- 6.7%; p = 0.6).

107 ir primary caregiver (odds ratio [OR] = 1.7, p = 0.029, 95% CI [1.06, 2.76], d = 0.29).

108 : 4.0; 95% confidence interval: 2.08 to 7.7; p < 0.0001).

109 re higher after coronary CTA ($995 vs. $718; p < 0.001).

110 0.54; 95% confidence interval: 0.41 to 0.72; p < 0.0001).

111 45; p = 0.03; HR: 0.59; p = 0.027; HR: 0.73; p = 0.035; HR: 0.48; p = 0.0003, respectively).

112 the early diastolic strain rate (r = -0.782, p < 0.001) and moderately correlated with the radial sys

113 st quintile) (OR = 2.68; 95% CI: 1.06, 6.79; p = 0.04 for BC-by-CRP-interaction).

114 hose with CNS complications (75.8% vs 37.8%; p < 0.001) and varied by type of CNS injury; mortality w

115 gitation moderate or higher (19.4% vs. 6.8%; p = 0.003).

116 identified as a risk factor of BPD (OR 1.8, p = 5.3 x 10(-5)), independently of the robust antenatal

117 in (Hb) status (-2.6 g/l; 95% CI -4.5, -0.8; p = 0.005).

118 3 years were closely interrelated (r = 0.81, p < 0.001).

119 3), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p < 0.001) compared with warfarin.

120 ome Scale as a continuous outcome (R = 0.82; p = 0.001; z score, 3.39).

121 reported QoL (MD = -0.02, 95% CI -1.22-0.82; p = 0.97) for people with dementia, or caregivers' gener

122 ission in response to drawdown (R(2) = 0.84, p < 0.01), suggesting that eutrophication magnifies the

123 95% confidence interval [CI]: 0.50 to 0.84; p = 0.001), although there was still no significant diff

124 le parameters (AUROC 0.76; 95%CI: 0.65-0.86, p = 0.02).

125 or in CRC (HR = 1.452, 95% CI = 1.118-1.884, p = 0.005).

126 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95%

127 ion (adjusted hazard ratio range, 0.43-0.89; p < 0.001).

128 if the tax were not in place, but rose 6.9% (p < 0.001) for non-Berkeley stores.

129 p = 0.4289) or 5-year LTP (73.3% vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

130 ue than for the intermediate hues (Z = -2.9, p = 0.004).

131 : 2.73; 95% confidence interval: 1.2 to 5.9; p = 0.01).

132 difference [MD] = -0.55, 95% CI -2.00-0.90; p = 0.45) and self-reported QoL (MD = -0.02, 95% CI -1.2

133 8; beta = 1.461, p = 0.005 and beta = 1.902, p = 0.002, respectively).

134 health status (MD = 0.13, 95% CI -1.65-1.91; p = 0.89).

135 95% confidence interval [CI]: 0.62 to 0.92; p = 0.005), whereas in patients with DCM, no such differ

136 ear (adjusted hazard ratio range, 1.30-1.92; p < 0.001), which was attenuated in those who received r

137 d to soil humus C accumulation (R(2) = 0.94, p < 0.001).

138 west tertile (OR = 1.58, 95% CI = 1.29-1.94, p < 0.001) and similarly prevalent in the highest tertil

139 creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.03), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p <

140 e mortality (HR: 0.90; 95% CI: 0.84 to 0.96; p = 0.002), but not with HF readmission (HR: 0.93; 95% C

141 nt period than at the baseline, Z >/= -1.97, p </= .04.

142 al thromboplastin time (hazards ratio, 0.98; p = 0.002) and decreased platelet count (hazards ratio,

143 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04).

144 0.039), from the adult's bedroom for BDE-99 (p < 0.019) and from all rooms for BDE-99 (p < 0.020) and

145 9 (p < 0.019) and from all rooms for BDE-99 (p < 0.020) and BB-209 (p < 0.048).

146 living rooms for BDE-47 (p < 0.035), BDE-99 (p < 0.035), and BDE-153 (p < 0.039), from the adult's be

147 virus production was significantly affected (p < 0.05) after treatment with paclitaxel or nocodazole

148 RNA expression ex-vivo than either GG or AG (p < 0.001) in total peripheral blood mononuclear cells.

149 between islet cadmium content and both age (p = 0.048, R(2) = 0.09) and female gender (women: 36.88

150 In a univariate analysis, higher age (p = 0.0018), male gender (p = 0.019), high risk cytogene

151 d third (median, 0 vs 10.5) assessments (all p < 0.001).

152 nal, motor, and cognitive deterioration (all p < 0.001), independent of mutant HTT CAG repeat size.

153 of the stratified variables were found (all p > 0.05).

154 erides with rs9939609 on BMI (p = 0.0005 and p = 5 x 10(-7), respectively).

155 th alterations in these genes (p = 0.018 and p = 0.006, respectively).

156 no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

157 expressed regions with >|2| fold change and p </= 0.05.

158 were more likely to receive anticoagulation (p < 0.001).

159 CD4 cells than those with NRTI-DRMs on ART (p = 0.042).

160 ysis, an exome-wide significant association (p < 2.5 x 10(-6)) was observed with CCDC62 (SKAT-O [p =

161 fasting triglycerides with rs9939609 on BMI (p = 0.0005 and p = 5 x 10(-7), respectively).

162 d (ie, extracellular [p = 0.001], cell body [p = 0.003], and neuritic/glial-processes [p = 0.004]).

163 in the mild and moderate-severe groups (both p < 0.001); (2) the mean cone-mediated PLR was reduced s

164 As (<500 bp) than the larger ones (>500 bp) (p < 0.01).

165 nt severity for both ITI (p = 0.01) and BTB (p = 0.05) was significantly decreased in the navigation

166 ntrols (34.35 degrees C [34-34.8 degrees C]; p < 0.0001).

167 009] and Instituto de Pesquisas de Cananeia [p = 0.03]) and CD8(+) T-cell frequency (p = 0.04) correl

168 ne H3+ (a marker of mitosis) cardiomyocytes (p = 0.04), and noncardiomyocytes (p = 0.0002) than did t

169 confirmed in 4 (2.1%) versus 6 (3.2%) cases (p = 0.79).

170 mine increases were observed in the caudate (p = 0.1) or putamen (p = 0.8) following methylphenidate

171 MSTN-edited fry had more muscle cells (p < 0.001) than controls, and the mean body weight of ge

172 x 10(-7)], combined multivariate collapsing [p = 1.48 x 10(-6)], and burden of rare variants [p = 1.4

173 n 88% compared to 19.6% in healthy controls (p = 4.1 x 10(-11) ).

174 despite baseline values lower than controls (p < 0.05), and fractional anisotropy (FA) was lower with

175 (>30%; false discovery rate [FDR] corrected p < 0.0008) and nontrained WM tests after adaptive WMT (

176 WM tests after adaptive WMT (FDR corrected, p </= 0.001), but not after nonadaptive WMT (training by

177 ve WMT (training by training type corrected, p = 0.01 to p = 0.05) 1 month later.

178 those measuring hs-cTnT rather than hs-cTnI (p = 0.027).

179 gender (p = 0.019), high risk cytogenetics (p = 0.002), higher IDO-1 mRNA (p = 0.005), higher compos

180 ohorts, including a slightly faster decline (p = 0.021) on the MMSE for Asians (-0.20 SD/decade, 95%

181 en lesion volume and neurocognitive decline (p = 0.0022).

182 trols with concentrations further decreased (p < 0.05) in a TLR5(392Stop) SNP rUTI subgroup.

183 ality showed significant climate dependence (p < 0.001) after adjusting for socioeconomic factors.

184 subjects and 5.6% in patients with devices (p = 0.25) Neurocognitive function was similar in control

185 verall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

186 group (coefficients significantly different, p = 0.012).

187 f tumor driver mutations are differentiated (p < 0.05) over the racial groups in five cancers, such a

188 V was associated with tumor differentiation (p < 0.001).

189 ity dose trends for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), poss

190 ase (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to competing causes of death ov

191 all compartments studied (ie, extracellular [p = 0.001], cell body [p = 0.003], and neuritic/glial-pr

192 ed in 18.2% of eyes; 86.4% were myopic eyes (p = 0.01); 81.8% occurred within a 120 days-period follo

193 (-0.140 standard deviations per risk factor, p < 0.0001) and remained significant after adjustment fo

194 hose in refractory ventricular fibrillation (p = 0.017).

195 associated with 91% reduced use of firewood (p < 0.01), substantial time savings for primary cooks, a

196 eia [p = 0.03]) and CD8(+) T-cell frequency (p = 0.04) correlate with T4 to T9 spinal cord cross-sect

197 lysis, higher age (p = 0.0018), male gender (p = 0.019), high risk cytogenetics (p = 0.002), higher I

198 dentified 64, 5, 21 and 1 significant genes (p < 0.05 after Bonferroni correction) associated with T1

199 than those with alterations in these genes (p = 0.018 and p = 0.006, respectively).

200 During differentiation, Gnas(+/p-) cells showed diminished pCREB, beta-catenin and cycl

201 d BRVO groups compared to the control group (p < 0.001).

202 reduced compared to controls in CRVO group (p < 0.001) and PFVD of choriocapillaris was significantl

203 significantly in the moderate-severe group (p = 0.008); (3) no significant differences in the mean r

204 the most electron donating functional group (p-(CH3CH2)2NPh-MoS2) is the most efficient catalyst for

205 , the right ventricle dilated in all groups (p < 0.01 for all).

206 in the affected hemi fields in BRVO groups (p < 0.001).

207 mptying time (t50) was slower in AN than HC (p = 0.016) and OB (p = 0.007), and a negative associatio

208 urther under bolus resuscitation (-10 mm Hg; p < 0.001) and was lower under bolus resuscitation than

209 ision assist, closed loop: 24 +/- 0.4 mm Hg; p < 0.05) and hemoglobin concentration were significantl

210 57 +/- 2 mm Hg, closed loop: 69 +/- 4 mm Hg; p = 0.036).

211 ps (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.7 mm Hg; p = 0.17), whereas the ViR group had more frequent post-

212 ng rate at presentation was observed in HHT (p = 0.069) and an increased rate of giant venous pouch i

213 ith COD:N = 4:1 showed significantly higher (p = 0.028) N2O accumulation (8.5.3 +/- 0.9% of the total

214 s independently predictive of both hospital (p = 0.001) and 90-day mortality (p < 0.0001).

215 n extubation readiness test within 10 hours (p < 0.001).

216 NA rhythms were delayed by 0.97 +/- 0.29 hr (p < 0.01), indicating that human molecular clocks may be

217 Apnea occurred more than hypopnea (p < 0.0001).

218 17.2 % for the resident-staffed medical ICU; p = 0.001).

219 40.0% for the resident-staffed medical ICU; p = 0.002), and had a higher severity of illness by rela

220 /- 16.9 yr for resident-staffed medical ICU; p = 0.019), more likely to be transferred from an inpati

221 children in whom no mutation was identified (p = 0.097).

222 er compared with HIV-uninfected individuals (p = 0.0001).

223 improved significantly after alcohol intake (p = 0.016).

224 effects, with no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

225 Impingement severity for both ITI (p = 0.01) and BTB (p = 0.05) was significantly decreased

226 vaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.001).

227 tern is more pronounced at higher latitudes (p = 0.023).

228 40(+)) reduced compared with pre-ART levels (p = 0.0001), but remaining significantly higher compared

229 E2 plasma levels (p = .092) and time period of measurement (p = .975) did

230 ound mean acoustic intensity than MBControl (p < 0.05), however MBDual demonstrated no additional inc

231 ol/g protein +/- standard error of the mean, p = 0.040 by ANOVA).

232 s (p = .092) and time period of measurement (p = .975) did not significantly affect corneal parameter

233 in fold changes of urinary PAH metabolites (p < 0.002).

234 % vs. 24.7 +/- 2.2% in vehicle-treated mice; p < 0.05) but not in the RA CMC group (24.1 +/- 1.2%).

235 t a pressure of 55 mmHg for 50 milliseconds (p < 0.05).

236 ared to femoral access: 10 min versus 9 min (p < 0.0001) and 65 Gy.cm(2) versus 59 Gy.cm(2) (p = 0.00

237 rial volumes (106 +/- 36 ml to 69 +/- 24 ml; p < 0.001).

238 d-diastolic (161 +/- 36 ml to 122 +/- 30 ml; p < 0.001) and left atrial volumes (106 +/- 36 ml to 69

239 13 [7 to 25] pg/mol vs. 18 [9 to 36] pg/mol; p < 0.001; n = 340).

240 h hospital (p = 0.001) and 90-day mortality (p < 0.0001).

241 n independent predictor of 1-year mortality (p < 0.0005) and 1-year death and/or HF (hazard ratio: 1.

242 cytogenetics (p = 0.002), higher IDO-1 mRNA (p = 0.005), higher composite IDO-1 score (p < 0.0001) an

243 area responses to loud sounds (multivariate p = .007) compared with trauma-exposed participants with

244 er with radial than femoral access (41 muSv; p = 0.02).

245 n water-soluble organic carbon and nitrogen (p < 0.01) in household air samples.

246 omyocytes (p = 0.04), and noncardiomyocytes (p = 0.0002) than did the placebo group in some regions o

247 x 10(-6)) was observed with CCDC62 (SKAT-O [p = 6.89 x 10(-7)], combined multivariate collapsing [p

248 was slower in AN than HC (p = 0.016) and OB (p = 0.007), and a negative association between t50 and B

249 cally significant differences were observed (p < 0.05).

250 e visual function ( 58 fold increase in OKR, p < 0.001, 3 fold increase in VMR, p < 0.05).

251 tivity in at-risk than control participants (p < .006).

252 (41%) than in CASPR2-IgG-positive patients (p = 0.033).

253 rogenism alone showed a metabolic phenotype (p < 0.05) and insulin resistance (p < 0.001).

254 9 +/- 2.3 mmHg lower in the supine position (p < .05).

255 ecruitment when added to murine air pouches (p < 0.05).

256 y [p = 0.003], and neuritic/glial-processes [p = 0.004]).

257 ta and TNF-alpha expression, and production (p < 0.001).

258 4.11 vs men: 21.22 +/- 3.65 nmol/g protein, p = 0.007) was observed.

259 pGs in the gene proline rich 5 like (PRR5L) (p < 10(4)).

260 UROC] for wPRx was 0.73 versus 0.66 for PRx, p = 0.003).

261 bserved in the caudate (p = 0.1) or putamen (p = 0.8) following methylphenidate injection.

262 hythmia free-survival: 85% vs. 59%; log-rank p < 0.001).

263 inal-douche BD2 concentrations were reduced (p < 0.05) in women suffering rUTIs, compared to age-matc

264 iculus, right caudate and occipital regions (p < 0.05).

265 phenotype (p < 0.05) and insulin resistance (p < 0.001).

266 g to LGE presence and absence, respectively (p < 0.001).

267 control and hyperoxia groups, respectively (p = 0.077).

268 m(3) vs. 177.3 +/- 94.3 mm(3), respectively; p = 0.73).

269 oth at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively;

270 (17.7%, 12.7%, 4.9%, and 5.8%, respectively; p < 0.05).

271 and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006).

272 me (mean +/- SD) (87 +/- 41 vs 109 +/- 33 s; p = 0.037) and a longer delay before the start of chest

273 est compressions (109 +/- 77 vs 70 +/- 56 s; p = 0.038).

274 nominal association with gout in our sample (p < 0.05).

275 ty scores (Expanded Disability Status Scale [p = 0.009] and Instituto de Pesquisas de Cananeia [p = 0

276 A (p = 0.005), higher composite IDO-1 score (p < 0.0001) and not undergoing allogeneic stem cell tran

277 rgoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor overall survival.

278 nd improved renal function in CKD-RDN sheep (p < 0.0001 for 2 and 5 months vs. pre-RDN).

279 association was only marginally significant (p = 0.054).

280 litudes and PPGDC levels showed significant (p < 0.001) changes during the increase in shear rates an

281 ted in 2006, about 29.5% showed significant (p < 0.05) increasing trends of MODIS NDVI after implemen

282 necrotic/apoptotic injury and significantly (p < 0.05) improved function and recipient Lewis rat surv

283 s in the outer endodermis are significantly (p < 0.01) higher than those in the inner endodermis.

284 degrees C) storage exhibited significantly (p < 0.05) decreased acute necrotic/apoptotic injury and

285 es to date using a score of 62 RA risk SNPs (p < 5 * 10(-8)) as instrumental variable (IV).

286 -/-) macrophages following TLR2 stimulation (p < 0.01).

287 F had significantly higher tensile strength (p = 0.00).

288 ons were stronger in North American studies (p = 0.010) and those measuring hs-cTnT rather than hs-cT

289 the genes that were identified in our study (p = 1.54 x 10(-17)).

290 arge had 12.4% greater costs than survivors (p < 0.01; 99% CI = 9.3-15.5%) after multivariable adjust

291 e ViV group (28.7% vs. 12.6%; log-rank test, p = 0.01).

292 ning by training type corrected, p = 0.01 to p = 0.05) 1 month later.

293 of 176.7 +/- 152.4 s of arc after training (p < 0.01).

294 control versus 95.72 x 106/l +/- 8.0 trauma, p < 0.05) and reduced leukocyte cytokine secretion in re

295 control versus 1,092 x 106/l +/- 165 trauma, p < 0.0005) and CD14+HLA-DRlow/- monocytes (34.96 x 106/

296 5% vs 50.0% with standard medical treatment; p = 0.004), especially in patients with multiple organ f

297 ation functional class I or II at follow-up; p < 0.0001 vs. baseline) and Minnesota Heart Failure Que

298 1.48 x 10(-6)], and burden of rare variants [p = 1.48 x 10(-6)]).

299 in OKR, p < 0.001, 3 fold increase in VMR, p < 0.05).

300 lume hospital were younger (64.7 vs 72.7 yr; p < 0.001) and were more likely to have commercial insur